Drug Approval | October 30, 2025
Granules India’s facility secures FDA EIR with 'VAI’
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
The event will be attended by 35,000+ industry professionals
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Subscribe To Our Newsletter & Stay Updated
